Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24132Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | BURZYKOWSKI, Tomasz | - |
| dc.contributor.author | Saad, Everardo D. | - |
| dc.contributor.author | BUYSE, Marc | - |
| dc.date.accessioned | 2017-08-07T13:07:44Z | - |
| dc.date.available | 2017-08-07T13:07:44Z | - |
| dc.date.issued | 2017 | - |
| dc.identifier.citation | JAMA ONCOLOGY, 3(3), p. 416-416 | - |
| dc.identifier.issn | 2374-2437 | - |
| dc.identifier.uri | http://hdl.handle.net/1942/24132 | - |
| dc.language.iso | en | - |
| dc.publisher | AMER MEDICAL ASSOC | - |
| dc.rights | (c) 2017 American Medical Association. All rights reserved. | - |
| dc.title | Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question | - |
| dc.type | Journal Contribution | - |
| dc.identifier.epage | 416 | - |
| dc.identifier.issue | 3 | - |
| dc.identifier.spage | 416 | - |
| dc.identifier.volume | 3 | - |
| local.format.pages | 1 | - |
| local.bibliographicCitation.jcat | A1 | - |
| dc.description.notes | [Burzykowski, Tomasz; Saad, Everardo D.] Int Inst Drug Dev, 30 Ave Provinciale, B-1340 Louvain La Neuve, Belgium. [Burzykowski, Tomasz; Buyse, Marc] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, Hasselt, Belgium. [Saad, Everardo D.] Dendrix Res, Sao Paulo, Brazil. [Buyse, Marc] Int Inst Drug Dev, San Francisco, CA USA. | - |
| local.publisher.place | CHICAGO | - |
| local.type.refereed | Refereed | - |
| local.type.specified | Letter | - |
| dc.identifier.doi | 10.1001/jamaoncol.2016.3941 | - |
| dc.identifier.isi | 000397491400023 | - |
| item.contributor | BURZYKOWSKI, Tomasz | - |
| item.contributor | Saad, Everardo D. | - |
| item.contributor | BUYSE, Marc | - |
| item.accessRights | Open Access | - |
| item.fullcitation | BURZYKOWSKI, Tomasz; Saad, Everardo D. & BUYSE, Marc (2017) Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question. In: JAMA ONCOLOGY, 3(3), p. 416-416. | - |
| item.validation | ecoom 2018 | - |
| item.fulltext | With Fulltext | - |
| crisitem.journal.issn | 2374-2437 | - |
| crisitem.journal.eissn | 2374-2445 | - |
| Appears in Collections: | Research publications | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| burzykowski2016.pdf | Published version | 36.91 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.